ReviewActa pharmaceutica Sinica. B2024
Next-generation aluminum adjuvants: Immunomodulatory layered double hydroxide NanoAlum reengineered from first-line drugs.
Review in Acta pharmaceutica Sinica. B, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Linking Adjuvant Immune Stimulation to Spatiotemporal Dynamics via Cross-Scale Photoacoustic Microscopy.Chemical & biomedical imaging · 2026Article
- Smartly Assembled near-Micron RF-Responsive Agents Bridge Transarterial Embolization and Immunothermal Potentiation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Vaccine Adjuvants and Delivery Systems: A Comprehensive Review.International journal of molecular sciences · 2026Review
- Biomimetic Copper-Doped Nano-Aluminum Adjuvant Potentiates Therapy in Chemoresistant Acute Myeloid Leukemia.Advanced healthcare materials · 2026Article
- Adjuvant choice shapes macrophage activation and cytokine responses to freeze-thaw breast cancer antigens.BMC research notes · 2026Article
- Calcium/Aluminum-Cored Asymmetric Bilayer Nanoparticles for Codelivery of Ziyuglycoside II and PD-L1 siRNA Exert Anti-Breast Tumor Effects.Pharmaceutics · 2026Article
- Understanding obesity-cancer crosstalk to inform the immunomodulatory roles of anti-obesity nanotherapeutics.Materials today. Bio · 2026Review
- Bioactive LDH nanoplatforms for cancer therapy: Advances in modulating programmed cell death.Materials today. Bio · 2025Review
- Biomaterials nanoplatform-based tumor vaccines for immunotherapy.Bioactive materials · 2025Review
- Evaluation of a bivalent vaccine composed of iron scavenger receptors PMI1426 and PMI1945 againstFuture microbiology · 2025Article
- Layered double hydroxides for regenerative nanomedicine and tissue engineering: recent advances and future perspectives.Journal of nanobiotechnology · 2025Review
- Advancing cancer gene therapy: the emerging role of nanoparticle delivery systems.Journal of nanobiotechnology · 2025Review
- The origin of autoimmune diseases: is there a role for ancestral HLA-II haplotypes in immune hyperactivity.Frontiers in immunology · 2025Review
- Immunogenic Potential of a Multi-Peptide Vaccine Construct Against Uropathogenic Escherichia coli-Associated Urinary Tract Infection.Iranian biomedical journal · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aluminum adjuvants (Alum), approved by the US Food and Drug Administration, have been extensively used in vaccines containing recombinant antigens, subunits of pathogens, or toxins for almost a century. While Alums typically elicit strong humoral immune responses, their ability to induce cellular and mucosal immunity is limited. As an alternative, layered double hydroxide (LDH), a widely used antacid, has emerged as a novel class of potent nano-aluminum adjuvants (NanoAlum), demonstrating advantageous physicochemical properties, biocompatibility and adjuvanticity in both humoral and cellular immune responses. In this review, we summarize and compare the advantages and disadvantages of Alum and NanoAlum in these properties and their performance as adjuvants. Moreover, we propose the key features for ideal adjuvants and demonstrate that LDH NanoAlum is a promising candidate by summarizing its current progress in immunotherapeutic cancer treatments. Finally, we conclude the review by offering our integrated perspectives about the remaining challenges and future directions for NanoAlum's application in preclinical/clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.